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ABSTRACT
Objective: The objective of this selective EBM review is to determine whether or not “Is pulse
ultrasound effective at decreasing pain in patients with knee osteoarthritis?”
Study Design: Review of three double-blind, randomized, controlled trials published after the
year 2013.
Data Sources: Studies were published in peer-reviewed journals, found using PubMed database
searches and were selected based on patient-oriented outcomes.
Outcome Measured: The pain Visual Analog Scale is a unidimensional, continuous scale of pain
intensity usually 10cm in length, anchored by “no pain” (score of 0) and “worst imaginable pain”
(score of 10). Patients self-report by placing a line on the scale to represent their current pain
intensity at the time of filling out the scale (Physiopedia contributors. Visual analog scale Web
site. https://www.physio-pedia.com/index.php?title=Visual_Analogue_Scale&oldid=222925.
Updated 2019. Accessed December 1, 2019).
Results: In the study conducted by Cakir et al. (Efficacy of therapeutic ultrasound for the
management of knee osteoarthritis. Am J Phys Med Rehabil. 2014;93(5):405-412.
doi:10.1097/PHM.0000000000000033), the study did not record a significant reduction in pain
when comparing pulse ultrasound to placebo treatment at the end of 10 days of treatment (95%
CI 1.84 to 2.82). The trial performed by Jia et al. (Efficacy of focused low-intensity pulsed
ultrasound therapy for the management of knee osteoarthritis: A randomized, double blind,
placebo-controlled trial. Sci Rep. 2016;6:35453. Published 2016 Oct 17. doi:10.1038/srep35453)
found that pain with movement was significantly decreased in the pulse ultrasound group
compared to the placebo group at the end of treatment with a 5.44 score reduction on the Visual
Analog Scale (p=0.000). The study performed by Yildiz et al. (The effectiveness of ultrasound
treatment for the management of knee osteoarthritis: A randomized, placebo-controlled, double
blind study. Turk J Med Sci. 2015;45(6):1187-91. PMID: 26775369) showed a significant
reduction in pain with movement at the end of 10 days of treatment with a score decreased by
1.23 points more as opposed to the placebo (p=0.020).
Conclusion: The results of these studies showed that pulse ultrasound may decrease pain in
patients with knee osteoarthritis; however, further investigation with similar methods, follow-up,
and adjunctive treatment is warranted.
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INTRODUCTION
Osteoarthritis (OA) is a chronic, progressive, noninflammatory intra-articular disease in
which cartilage break down in the joint can lead to pain and eventually disability. Patients with
OA can be asymptomatic and only have evidence of OA on X-ray, but eventually, these patients
become symptomatic. Common symptoms of OA consist of morning stiffness less than 30
minutes, crepitus on active motion, bony tenderness and enlargement of the joint, no palpable
warmth of the synovium, and decrease range of motion.1 OA has a predilection for larger joints
like the hips and knees which leads to decrease mobility and function. Because of OA’s
definitively negative impact on the quality of life, people with OA are at an increased risk of
developing psychological disorders especially depression compared to the general population.2
Patients will often seek treatment to improve their mobility and decrease pain.
OA affects over 30 million people in the United States. The prevalence of symptomatic
knee OA in adults 60 years of age or older is approximately 10% in men and 13% in women.3
Because of the high prevalence of symptomatic knee OA, it has been estimated that OA accounts
for 2.5% of all healthcare visits for any cause, 10% of all hospitalizations, and 2% of ambulatory
visits. There are currently 25,500 orthopedic surgeons and 10,450 physician assistants in
orthopedics to help manage the more complicated cases requiring surgery and certain injections.
As of 2017, the estimated healthcare cost is $80 billion, and since OA can progress to disability,
it has been estimated that the cost of lost wages due to disability is $108 billion.4
Although the exact cause of OA is not known, it is generally recognized as multifactorial,
involving extra-articular and intra-articular risk factors that can be classified as nonmodifiable
and modifiable. Nonmodifiable risk factors are old age, female gender, and race. Since these risk
factors cannot be changed, modifiable risk factors such as obesity, knee injury, repetitive use of
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joints, bone density, muscle weakness, and joint laxity are the focus of therapy. Lifestyle
modifications play an important role in treating OA such as weight loss, repetitive use of joint,
and muscle weakness. Weight loss plays a large role since it improves symptoms and may reduce
disease progression. Joint laxity and muscle weakness can be managed using knee braces,
hydrotherapy, and physical therapy. Pharmacologic options for managing pain are topical
nonsteroidal anti-inflammatory drugs (NSAIDs), capsaicin cream, acetaminophen, and oral
NSAIDs like ibuprofen, naproxen, and celecoxib. More invasive options of treatment are intraarticular injections containing corticosteroids, hyaluronate or platelet-rich plasma. The most
definitive treatment option for advance cases where previous interventions mentioned are no
longer effective is a total joint replacement; however, patients are still at risk for having pain and
decreased mobility.
The treatment options mentioned all play an important role in treating and improving OA
symptoms, but since topical agents are less effective on large joints, which OA is more prone to
affect, this results in use of oral medications chronically and at a high dose. This is known to
cause harmful side effects such as GI bleeds and liver toxicity. Intra-articular injections carry the
risk of further cartilage break down due to corticosteroids and infection due to the invasiveness
of the procedure. Total joint replacement is not always an option because of the patient's age and
other co-morbidities.4 Because of the prevalence of OA, drawbacks related to oral medications,
and more invasive procedures, it is important to have other treatment modalities to improve
function and decrease pain. The current understanding regarding ultrasound (US) therapy is that
low-frequency continuous ultrasound has a thermal effect whereas pulse US used at a low
frequency while lacking a thermal effect is more likely to increase chemical activity and fluid
flow rate as well as change the permeability of cell membranes. The current theory around pulse

Dieffenderfer: OA and Pulse Ultrasound

3

ultrasound is its effects will cause cartilage to stop breaking down and even possibly
regenerate.5,6 Pulse US has been shown to be effective for bone regeneration therapy for
nonunion bone fractures for whom surgery is considered too high a risk.7 Thus, pulse US may be
an effective adjuvant care option to oral medications. The hope being it will decreasing the
necessary dose for pain relief and be a safe and effective option for those unable to receive total
joint replacement surgeries. The goal of this paper is to evaluate the efficacy of pulse US
decreasing pain in patients with knee OA by analyzing three double-blind randomized controlled
trials.
OBJECTIVE
The objective of this selective evidence-based medicine (EBM) review is to determine
whether or not pulse ultrasound is effective at decreasing pain in patients with knee
osteoarthritis.
METHODS
The criteria used for inclusion was based on population, intervention, comparison, and
outcomes. The population had to be patients with symptomatic knee OA. The intervention used
was pulse US, used for a total of 10 days, compared to a control group that received placebo US.
The outcome was measured using a Visual Analog Scale (VAS) which is a self-reporting
continuous scale. All three studies are double-blind randomized controlled trials.
Appropriate articles were selected via PubMed and Cochrane Collaboration in the
English language by using the keywords "knee osteoarthritis" and "ultrasound therapy." All
articles were published in peer-reviewed journals and were selected based on their relevance to
the clinical question that had patient-oriented outcomes (POEMs). Inclusion criteria consisted of
studies being published after 2013, randomized controlled trials, and the study was conducted on
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humans. Exclusion criteria consisted of studies published in 2013 or earlier and preexisting
Cochrane systematic reviews. P-value and confidence interval was used as the statistical value in
these articles. Cakir et al.8 and Jia et al.9 used the confidence interval in their study. P-value was
used in Jia et al. and Yildiz et al.5 In Table 1, each of the selected articles’ specific demographics
and characteristics are shown.
Table 1 - Demographics & Characteristics of included studies
Study Type
#
Age
Inclusion
Exclusion Criteria
Pts (yrs) Criteria
Cakir8 Double 60 40-80 Patients who Patients who have
received physical
(2014) -blind
years have knee
therapy, intra-articular
RCT
old
pain for at
corticosteroid therapy
least 6 mo,
or chondroprotective
with a
agents in the past 30d,
or
Kellgrenviscosupplementation
Lawrence
treatment within the
rating of II
past 6mo, or major
and III
surgery
Patients who have
Jia9
Double 106 >40 Patient who
received oral or intra(2016) -blind
years have knee
articular corticosteroids
RCT
old
pain with a
use within past 6 mo,
Kellgren and physiotherapy, physical
Lawrence
therapy, acupuncture
treatment, or history of
rating of II,
NSAID or symptomatic
and III, and
slow-acting drugs for
limitations
OA within the previous
on most days 30d
within the
past 6
months
Yildiz Double 90 40-65 Pts who have Patients who have
5
received intra-articular
-blind
years knee pain
steroid and/or
(2015) RCT
old
with a
hyaluronate injection in
Kellgren and the past 6 months, knee
Lawrence
surgery or arthroscopy
in the last year, and
rating of II
physical treatment in
and III
the last 3 months.

W/D

Interventions

2

Pulse US at a
frequency of
1MHz with
intensity of 1
W/cm^2 at a
pulse ratio of
1:4 for 12
minutes

9

Focused lowintensity pulsed
US therapy at a
frequency of
0.6MHz with
intensity of
120mW/cm^2
at a pulse ratio
of 1:5 for 20
minutes

0

Pulse US at a
frequency of
1MHz with
intensity of 1.5
W/cm^2 at a
pulse ratio of
1:5 for 5
minutes
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OUTCOMES MEASURED
Outcomes for this EBM review were measured using the Visual Analog Scale (VAS).
Patients self-report by placing a line on the scale to represent their current pain intensity at the
time of filling out the scale.10 The VAS was measured at baseline and again at the end of
treatment for all three articles.
RESULTS
For this EBM review, the three studies selected compared pulse US against placebo US.
Each study had a group of participants treated with 10 days of pulse US therapy against a group
treated with placebo US for the same duration. Their outcomes were measured using VAS. The
p-value for Jia et al.9 and Yildiz et al.5 are listed in Table 2 and show the statistical significance
of pulse US against placebo US. The confidence interval for Cakir et al.8 and Jia et al.9 are listed
in Table 3. The study conducted by Cakir et al.8 shows that the confidence interval is wider than
Jia et al.9 indicating a lower probability effect compared to Jia et al.9 study.
TABLE 2. End of treatment p value comparing Pulse US vs Placebo US
P-value

Jia et al.

Yildiz et al.

0.000

<0.01

*p-value <0.05 is considered statistically significant
TABLE 3. VAS mean change from baseline confidence interval comparing Pulse US vs
Placebo US
VAS mean change from

Pulse US

Placebo US

1.84 to 2.82

2.45 to 4.15

5.05 to 5.79

4.08 to 4.88

baseline 95% CI for Cakir et al.
VAS mean change from
baseline 95% CI for Jia et al.
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In the first study performed by Cakir et al.8, 60 participants were accepted into the trial
after being screened for eligibility. The inclusion criteria were participants had to be outpatients
with knee pain for at least 6 months and diagnosed with OA using the American College of
Rheumatology (ACR) criteria. Patients were excluded if they had been diagnosed in the past
with joint infection, neoplasm, diabetes mellitus, paresis, osteonecrosis, recent trauma, pregnant
or lactating, and poor general health status. Additional inclusion and exclusion criteria can be
seen in Table 1. Participants were not allowed to take any NSAIDs within 1 week of the study,
but during the trial, patients could take up to 2000mg/d of paracetamol. Also, all patients were
given a home exercise program to perform regularly during the trial.8
Patients were then randomized into three treatment groups: continuous US, pulse US, and
placebo US. The focus of this EBM review will be on pulse US group and placebo US. The pulse
US was administered at a frequency of 1 MHz with an intensity of 1 W/cm2 with a pulse ratio of
1:4.8 The US probe was placed in full contact over the painful areas in the knee and each
treatment last 12 minutes. The patients in the placebo US received the same setup, but the power
was turned off. Only 2 patients withdrew from the trial. One patient withdrew for health
problems not related to the trial and the other due to time constraints. No adverse effects were
noted during the trial.8
According to the study, there was a significant reduction in pain with both pulse US and
placebo US (p<0.05) as illustrated in Table 4, but there was no statistical significance between
the groups. The confidence interval was calculated for the mean change from baseline to end of
study for placebo US and pulse US as seen in Table 3. The low probability of effective treatment
as indicated by the confidence interval demonstrates that it was more likely that random chance
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resulted in any change in pain than pulse US; thus, pulse US was not effective in decreasing pain
associated with knee OA.8

TABLE 4. Cakir et al VAS score at baseline and end of treatment
Pulse US

Placebo US

VAS at Baseline + SD

7.30 + 1.99

7.22 + 2.18

VAS at End of Treatment + SD

4.87 + 1.86

3.94 + 2.72

In the second study done by Jia et al.9, 106 participants were accepted into the trial after
being screened for eligibility. Inclusion criteria was knee OA meeting the ACR criteria.
Exclusion criteria included rheumatoid arthritis, gouty arthritis, infectious arthritis, history of
knee joint replacement, and medical conditions that exclude them from safe exercise. In table 1,
additional inclusion and exclusion criteria are included. Participants were instructed to take a
75mg diclofenac sodium-release tablet once daily for the 10-day treatment period.9
Participants were then randomized into two treatment groups: focused low-intensity
pulsed US and placebo US. The pulse US was administered at a frequency of 0.6MHz with an
intensity of 120mW/cm2 with a pulse ratio of 1:5. Four US probes were placed close to the
surface of the skin in four particular locations around the knee with the focus being on the
cartilage of the lateral and medial femoral condyles.9 The treatment duration was 20 minutes. A
total of 9 patients withdrew from the trial. Two patients withdrew for unknown reasons, 5
withdrew due to violation of study protocol, and two refused treatment. There were no adverse
effects reported relating to pulse US, but some participants had minor NSAID related adverse
effects.9
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The results show a significant reduction (p<0.05) in pain after intervention in both
groups, but VAS score reduction was greater in the pulse US group compared to placebo US
(Table 5). The confidence interval for this study was narrow indicating a high probability of the
treatment lowering pain with knee OA (Table 3). The statistical significance (Table 2) between
pulse US and placebo US indicates that pulse US is effective at lowering pain in knee OA.9
TABLE 5. Jia et al VAS score at baseline and end of treatment
Pulse US

Placebo US

VAS at Baseline + SD

6.98 + 1.06

6.76 + 1.02

VAS at End of Treatment + SD

1.54 + 0.81

2.28 + 1.01

The third study performed by Yildiz et al.5 had 90 participants that met the criteria for
their study. The inclusion criteria was outpatients with symptomatic knee pain. Exclusion criteria
included patients with secondary knee OA, active synovitis, symptomatic hip, foot and ankle
disease, neurologic deficits in a lower extremity, and recent trauma. Additional inclusion and
exclusion criteria are included in Table 1. Patients were informed that they could take up to
1,500mg/d of paracetamol. Participants were also given a home exercise program to perform 3
times a week for 8 weeks.5
Patients were then randomized into three treatment groups: continuous US, pulse US, and
placebo US. Pulse US was administered at a frequency of 1MHz with an intensity of 1.5 W/cm2
with a pulse ratio of 1:5.5 The treatment duration was 5 minutes. None of the study participants
withdrew and no adverse effects related to pulse US were recorded. Table 6 shows the reduction
in the VAS score at baseline and the end of treatment. The study's results show a statistically
significant reduction in VAS score with the pulse US group (Table 2) indicating that pulse US is
effective at decreasing pain in knee OA.5
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TABLE 6. Yildiz et al VAS score at baseline and end of treatment
Pulse US

Placebo US

VAS at Baseline + SD

8.60 + 1.61

8.93 + 1.44

VAS at End of Treatment + SD

5.17 + 2.02

6.73 + 2.89

DISCUSSION
The goal of this review is to determine if pulse US is effective at decreasing pain in knee
OA, but all three randomized controlled trials have a slight variance in their methods and
adjunctive care during treatment. These variances could affect the validity of their outcomes and
affects how well these studies can be compared. Cakir et al.8 and Yildiz et al.5 both used a
frequency of 1MHz but had differing treatment durations and pulse ratios. Cakir et al.8 treatment
lasted for 12 minutes and had a pulse ratio of 1:4 whereas Yildiz et al.5 treatment lasted for 5
minutes and had a pulse ratio of 1:5. Jia et al.9 had the lowest frequency of 0.6MHz but
conversely had the longest treatment duration of 20 minutes. With a lower frequency, the
penetration by US is deeper which could affect treatment outcomes.6 Jia et al.9 and Yildiz et al.5
had a clearly outlined placement for their US probes; therefore, for each participant, the probe set
up was the exact same. Cakir et al.8 placed one probe over the location where the patient
complained of the most pain.
All three studies had slightly different approaches to adjunctive care during the pulse US
therapy. Cakir et al.8 had home exercises that included quadriceps isometric exercise, muscle
strength exercise, and lower extremity stretching that was to be performed at least 3 times a
week. Patients were also allowed to take up to 2000mg/day of paracetamol. The study did not
show if patients in the placebo US group took more paracetamol than the patients in the pulse US
group which could have influenced why both groups had a similar response to treatment. In the
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study conducted by Jia et al.9 the patients were instructed to take diclofenac sodium sustainedreleased 75mg tablets daily but were not given home exercise programs. This removes the
variable of whether or not patients were doing their exercises as instructed and for the correct
amount of time each week. Yildiz et al.5 patients were instructed that up to 1,500mg/d of
paracetamol could be taken. Again, it was not recorded how much each patient was taking each
day, and if there was a difference between the placebo group and the treatment group. Patients in
this study were also instructed to do quadriceps isometric exercises and strengthening exercises 3
times a day for the duration of the study.
Continuous ultrasound has been used in physical therapy for conditions like tendinitis and
bursitis since the 1950s.6 Currently, the FDA has approved US for tendinitis and bursitis but has
not approved it for the use of OA. Since the FDA has not approved it, insurance companies do
not recognize it as a billable treatment option for patients with OA. This will cause some
physical therapists to not administer US to their patients but rather choose more billable options.
It is important to note that US is a safe therapeutic and diagnostic tool because it lacks ionizing
radiation, energy exposure is low, and does not appear to accumulate in the tissue.6 It is safe for
the operator to use as well since air is a poor medium for US waves to travel through. Since in
physical therapy therapeutic levels of US are set at low frequency, there is no change of burns
and vascular injury as seen in high frequency and rapidly repeating treatments such as
lithotripsy.6
CONCLUSION
The evidence presented in this EBM review is inconclusive in determining whether pulse
ultrasound is effective at decreasing pain in knee osteoarthritis. The studies conducted by Cakir
et al.8 and Yildiz et al.9 could have tracked how much paracetamol patients were taking each day
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as well as tracking how diligent patients were being with their exercises. This could have further
clarified if medication and physical therapy was the main contributing factor for pain
improvement or if pulse US was the main factor for pain improvement. Future research of this
topic is many due to the lack of consistency between interventions as previously discussed. Some
areas of research could be in the duration of US therapy, pulse frequency and probe placement.
Jia et al.9 showed very promising results, and their study had the longest treatment time as well
as a lower frequency, but further studies need to be conducted to confirm efficacy.
In the face of an increasing number of total knee replacements due to OA and with the
current trend being younger patients getting total knee replacements further research into US
therapy should be done. This research shows that pulse US can potentially decrease OA pain if
coupled with the proper method and adjunctive care. If OA pain is decreased, then younger
patients could delay or prevent the need for a total knee replacement. Since total knee
replacements last an average of 10 years this would also decrease the need for total knee revision
surgeries; thus, reducing the current healthcare cost.11
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